Skip to main content
SpringerLink
Log in

Impact of Combined Oral Contraceptive Use on Exercise and Health in Female Athletes

  • Chapter
  • First Online:
Exercise and Human Reproduction

Abstract

Nearly half of girls and women between the ages of 15 and 24 years use hormonal contraceptives. The overall health and well-being of girls and women of any age is benefited by routine exercise; however, the impact of hormonal contraceptive use on the capacity to exercise has yet to be conclusively addressed. Since the development of combined hormonal contraceptives, the concentration of the estrogen component (ethinyl estradiol; EE) has been decreased and further development of the progesterone component has occurred to reduce the side effects and increase the safety profile. There is currently no information available regarding the impact of transdermal or vaginal combined hormonal contraceptives on exercise performance variables; therefore, this review focuses on the impact of oral contraceptive (OC) preparations on factors influencing exercise performance. Current findings do not indicate consistent changes in substrate utilization during aerobic or anaerobic exercise in women using OC preparations. In addition, the influence of exogenous steroid concentrations used in monophasic and triphasic OC preparations on endurance performance variables of ventilation and oxygen uptake (VO2) is unclear. Short-term duration of OC use, as well as the androgenic activity of the progestin, appears to cause a decrease in VO2 and increased ventilatory response, with the observed effects of exogenous steroids dissipating with long-term use. It appears that modern OC formulations do not have enough androgenic potency across a cycle to influence muscular strength; however, these formulations may have the potential to increase anaerobic capacity. A negative impact on reactive strength has been documented with monophasic OC use. Long-term use of OCs can lead to an increase in body fat percentage and may compromise bone health in female athletes. Aerobic and anaerobic performance could be negatively impacted by these changes in body composition. Among female athletes, OCs may be prescribed to treat menstrual cycle disturbances, such as amenorrhea and oligomenorrhea, which occur as a result of an energy deficit. It must be emphasized that the use of OCs alone is not effective in treating these menstrual cycle disturbances and should be administered in combination with nonpharmacologic treatment when the latter treatment alone has not been effective.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006–2010, and changes in patterns of use since 1995. Natl Health Stat Report. 2012(60):1–25.

    Google Scholar 

  2. Brynhildsen J, Lennartsson H, Klemetz M, Dahlquist P, Hedin B, Hammar M. Oral contraceptive use among female elite athletes and age-matched controls and its relation to low back pain. Acta Obstet Gynecol Scand. 1997;76(9):873–8.

    Article  CAS  PubMed  Google Scholar 

  3. Bennell K, White S, Crossley K. The oral contraceptive pill: a revolution for sportswomen? Br J Sports Med. 1999;33(4):231–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Carr BR. Uniqueness of oral contraceptive progestins. Contraception. 1998; 58(3 Suppl):23 (S-27 S; quiz 67 S).

    Article  Google Scholar 

  5. Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception. 2011;84(1):19–34.

    Article  CAS  PubMed  Google Scholar 

  6. Nappi C, Di Spiezio Sardo A, Acunzo G, Bifulco G, Tommaselli GA, Guida M, Di Carlo C. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception. 2003;67(5):355–9.

    Article  CAS  PubMed  Google Scholar 

  7. Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gulmezoglu AM. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev. 2011(5):CD004861.

    Google Scholar 

  8. Oslakovic S, Zadro R. Comparison of the impact of four generations of progestins on hemostatic variables. Clin Appl Thromb Hemost. 2014;20(4):448–55.

    Article  PubMed  Google Scholar 

  9. Szarewski A, Mansour D, Shulman LP. 50 years of “The Pill”: celebrating a golden anniversary. J Fam Plann Reprod Health Care. 2010;36(4):231–8.

    Article  PubMed  Google Scholar 

  10. Burrows M, Peters CE. The influence of oral contraceptives on athletic performance in female athletes. Sports Med. 2007;37(7):557–74.

    Article  PubMed  Google Scholar 

  11. Rubinstein ML, Halpern-Felsher BL, Irwin CE Jr. An evaluation of the use of the transdermal contraceptive patch in adolescents. J Adolesc Health. 2004;34(5):395–401.

    Article  PubMed  Google Scholar 

  12. Roumen FJ, D.R. Mishell J. The contraceptive vaginal ring, NuvaRing((R)), a decade after its introduction. Eur J Contracept Reprod Health Care. 2012;17(6):415–27.

    Article  PubMed  Google Scholar 

  13. Bemben DA, Boileau RA, Bahr JM, Nelson RA, Misner JE. Effects of oral contraceptives on hormonal and metabolic responses during exercise. Med Sci Sports Exerc. 1992;24(4):434–41.

    Article  CAS  PubMed  Google Scholar 

  14. Bonen A, Haynes FW, Graham TE. Substrate and hormonal responses to exercise in women using oral contraceptives. J Appl Physiol (1985). 1991;70(5):1917–27.

    CAS  Google Scholar 

  15. Casazza GA, Jacobs KA, Suh SH, Miller BF, Horning MA, Brooks GA. Menstrual cycle phase and oral contraceptive effects on triglyceride mobilization during exercise. J Appl Physiol (1985). 2004;97(1):302–9.

    Article  CAS  Google Scholar 

  16. Spellacy WN. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives. Am J Obstet Gynecol. 1982;142(6 Pt 2):732–4.

    CAS  PubMed  Google Scholar 

  17. Ashley CD, Kramer ML, Bishop P. Estrogen and substrate metabolism: a review of contradictory research. Sports Med. 2000;29(4):221–7.

    Article  CAS  PubMed  Google Scholar 

  18. Bernardes RP, Radomski MW. Growth hormone responses to continuous and intermittent exercise in females under oral contraceptive therapy. Eur J Appl Physiol Occup Physiol. 1998;79(1):24–9.

    Article  CAS  PubMed  Google Scholar 

  19. D’Eon TM, Sharoff C, Chipkin SR, Grow D, Ruby BC, Braun B. Regulation of exercise carbohydrate metabolism by estrogen and progesterone in women. Am J Physiol Endocrinol Metab. 2002;283(5):E1046–55.

    Article  PubMed  Google Scholar 

  20. Campbell SE, Febbraio MA. Effect of ovarian hormones on mitochondrial enzyme activity in the fat oxidation pathway of skeletal muscle. Am J Physiol Endocrinol Metab. 2001;281(4):E803–8.

    CAS  PubMed  Google Scholar 

  21. Sunderland C, Tunaley V, Horner F, Harmer D, Stokes KA. Menstrual cycle and oral contraceptives’ effects on growth hormone response to sprinting. Appl Physiol Nutr Metab. 2011;36(4):495–502.

    Article  CAS  PubMed  Google Scholar 

  22. Redman LM, Weatherby RP. Measuring performance during the menstrual cycle: a model using oral contraceptives. Med Sci Sports Exerc. 2004;36(1):130–6.

    Article  PubMed  Google Scholar 

  23. Jacobs KA, Casazza GA, Suh SH, Horning MA, Brooks GA. Fatty acid reesterification but not oxidation is increased by oral contraceptive use in women. J Appl Physiol (1985). 2005;98(5):1720–31.

    Article  CAS  Google Scholar 

  24. Suh SH, Casazza GA, Horning MA, Miller BF, Brooks GA. Effects of oral contraceptives on glucose flux and substrate oxidation rates during rest and exercise. J Appl Physiol (1985). 2003;94(1):285–94.

    Article  CAS  Google Scholar 

  25. Tremblay J, Peronnet F, Massicotte D, Lavoie C. Carbohydrate supplementation and sex differences in fuel selection during exercise. Med Sci Sports Exerc. 2010;42(7):1314–23.

    Article  CAS  PubMed  Google Scholar 

  26. Isacco L, Thivel D, Pelle AM, Zouhal H, Duclos M, Duche P, Boisseau N. Oral contraception and energy intake in women: impact on substrate oxidation during exercise. Appl Physiol Nutr Metab. 2012;37(4):646–56.

    Article  CAS  PubMed  Google Scholar 

  27. Rechichi C, Dawson B. Oral contraceptive cycle phase does not affect 200-m swim time trial performance. J Strength Cond Res. 2012;26(4):961–7.

    Article  PubMed  Google Scholar 

  28. Powers SK, Howley ET. Exercise metabolism. In: Powers SK, Howley ET, editors. Exercise physiology: theory and application to fitness and performance. McGraw Hill: New York; 2012 p. 68–90.

    Google Scholar 

  29. Rechichi C, Dawson B, Goodman C. Athletic performance and the oral contraceptive. Int J Sports Physiol Perform. 2009;4(2):151–62.

    PubMed  Google Scholar 

  30. Akin JW. Contraception. In: Ireland ML, Nattiv A, editors. The female athlete. Saunders: Philadelphia; 2002 p. 157–64.

    Google Scholar 

  31. Saris WH, Antoine JM, Brouns F, Fogelholm M, Gleeson M, Hespel P, Jeukendrup AE, Maughan RJ, Pannemans D, Stich V. PASSCLAIM—physical performance and fitness. Eur J Nutr. 2003;42(Suppl 1):I50–95.

    Article  PubMed  Google Scholar 

  32. Bangsbo J, Mohr M, Poulsen A, Perez-Gomez J, Krustrup P. Training and testing the elite athlete. J Exerc Sci Fit. 2006;4(1):1–13.

    Google Scholar 

  33. Giacomoni M, Falgairette G. Decreased submaximal oxygen uptake during short duration oral contraceptive use: a randomized cross-over trial in premenopausal women. Ergonomics. 2000;43(10):1559–70.

    Article  CAS  PubMed  Google Scholar 

  34. Huisveld IA, Hospers JE, Bernink MJ, Erich WB, Bouma BN. The effect of oral contraceptives and exercise on hemostatic and fibrinolytic mechanisms in trained women. Int J Sports Med. 1983;4(2):97–103.

    Article  CAS  PubMed  Google Scholar 

  35. Joyce S, Sabapathy S, Bulmer A, Minahan C. Effect of long-term oral contraceptive use on determinants of endurance performance. J Strength Cond Res. 2013;27(7):1891–6.

    Article  PubMed  Google Scholar 

  36. Rebelo AC, Zuttin RS, Verlengia R, Cesar Mde C, de Sa MF, da Silva E. Effect of low-dose combined oral contraceptive on aerobic capacity and anaerobic threshold level in active and sedentary young women. Contraception. 2010;81(4):309–15.

    Article  CAS  PubMed  Google Scholar 

  37. Vaiksaar S, Jurimae J, Maestu J, Purge P, Kalytka S, Shakhlina L, Jurimae T. No effect of menstrual cycle phase and oral contraceptive use on endurance performance in rowers. J Strength Cond Res. 2011;25(6):1571–8.

    Article  PubMed  Google Scholar 

  38. Lynch NJ, De Vito G, Nimmo MA. Low dosage monophasic oral contraceptive use and intermittent exercise performance and metabolism in humans. Eur J Appl Physiol. 2001;84(4):296–301.

    Article  CAS  PubMed  Google Scholar 

  39. McNeill AW, Mozingo E. Changes in the metabolic cost of standardized work associated with the use of an oral contraceptive. J Sports Med Phys Fitness. 1981;21(3):238–44.

    CAS  PubMed  Google Scholar 

  40. Casazza GA, Suh SH, Miller BF, Navazio FM, Brooks GA. Effects of oral contraceptives on peak exercise capacity. J Appl Physiol (1985). 2002;93(5):1698–702.

    Article  CAS  Google Scholar 

  41. Lebrun CM, Petit MA, McKenzie DC, Taunton JE, Prior JC. Decreased maximal aerobic capacity with use of a triphasic oral contraceptive in highly active women: a randomised controlled trial. Br J Sports Med. 2003;37(4):315–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Joyce S, Sabapathy S, Bulmer AC, Minahan C. The effect of prior eccentric exercise on heavy-intensity cycling: the role of gender and oral contraceptives. Eur J Appl Physiol. 2014;114(5):995–1003.

    Article  CAS  PubMed  Google Scholar 

  43. Notelovitz M, Zauner C, McKenzie L, Suggs Y, Fields C, Kitchens C. The effect of low-dose oral contraceptives on cardiorespiratory function, coagulation, and lipids in exercising young women: a preliminary report. Am J Obstet Gynecol. 1987;156(3):591–8.

    Article  CAS  PubMed  Google Scholar 

  44. England SJ, Farhi LE. Fluctuations in alveolar CO2 and in base excess during the menstrual cycle. Respir Physiol. 1976;26(2):157–61.

    Article  CAS  PubMed  Google Scholar 

  45. Rechichi C, Dawson B, Goodman C. Oral contraceptive phase has no effect on endurance test. Int J Sports Med. 2008;29(4):277–81.

    Article  CAS  PubMed  Google Scholar 

  46. Redman LM, Scroop GC, Westlander G, Norman RJ. Effect of a synthetic progestin on the exercise status of sedentary young women. J Clin Endocrinol Metab. 2005;90(7):3830–7.

    Article  CAS  PubMed  Google Scholar 

  47. Rechichi C, Dawson B. Effect of oral contraceptive cycle phase on performance in team sport players. J Sci Med Sport. 2009;12(1):190–5.

    Article  PubMed  Google Scholar 

  48. Gaebelein CJ, L.C. Senay J. Vascular volume changes during cycling and stepping in women at two hydration levels. Eur J Appl Physiol Occup Physiol. 1982;48(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  49. Lynch NJ, Nimmo MA. Effects of menstrual cycle phase and oral contraceptive use on intermittent exercise. Eur J Appl Physiol Occup Physiol. 1998;78(6):565–72.

    Article  CAS  PubMed  Google Scholar 

  50. Sunderland C, Nevill M. Effect of the menstrual cycle on performance of intermittent, high-intensity shuttle running in a hot environment. Eur J Appl Physiol. 2003;88(4–5):345–52.

    Article  CAS  PubMed  Google Scholar 

  51. Phillips SK, Sanderson AG, Birch K, Bruce SA, Woledge RC. Changes in maximal voluntary force of human adductor pollicis muscle during the menstrual cycle. J Physiol. 1996;496(Pt 2):551–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Sarwar R, Niclos BB, Rutherford OM. Changes in muscle strength, relaxation rate and fatiguability during the human menstrual cycle. J Physiol. 1996;493(Pt 1):267–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Elliott KJ, Cable NT, Reilly T. Does oral contraceptive use affect maximum force production in women? Br J Sports Med. 2005;39(1):15–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Peters C, Burrows M. Androgenicity of the progestin in oral contraceptives does not affect maximal leg strength. Contraception. 2006;74(6):487–91.

    Article  CAS  PubMed  Google Scholar 

  55. Ekenros L, Hirschberg AL, Heijne A, Friden C. Oral contraceptives do not affect muscle strength and hop performance in active women. Clin J Sport Med. 2013;23(3):202–7.

    Article  PubMed  Google Scholar 

  56. Bryner RW, Toffle RC, Ullrich IH, Yeater RA. Effect of low dose oral contraceptives on exercise performance. Br J Sports Med. 1996;30(1):36–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Coney P, Washenik K, Langley RG, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception. 2001;63(6):297–302.

    Article  CAS  PubMed  Google Scholar 

  58. Rickenlund A, Carlstrom K, Ekblom B, Brismar TB, Von Schoultz B, Hirschberg AL. Effects of oral contraceptives on body composition and physical performance in female athletes. J Clin Endocrinol Metab. 2004;89(9):4364–70.

    Article  CAS  PubMed  Google Scholar 

  59. Bonny AE, Secic M, Cromer BA. A longitudinal comparison of body composition changes in adolescent girls receiving hormonal contraception. J Adolesc Health. 2009;45(4):423–5.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Tantbirojn P, Taneepanichskul S. Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women. Contraception. 2002;66(6):401–5.

    Article  CAS  PubMed  Google Scholar 

  61. Procter-Gray E, Cobb KL, Crawford SL, Bachrach LK, Chirra A, Sowers M, Greendale GA, Nieves JW, Kent K, Kelsey JL. Effect of oral contraceptives on weight and body composition in young female runners. Med Sci Sports Exerc. 2008;40(7):1205–12.

    Article  CAS  PubMed  Google Scholar 

  62. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2006(1):CD003987.

    Google Scholar 

  63. Weaver CM, Teegarden D, Lyle RM, McCabe GP, McCabe LD, Proulx W, Kern M, Sedlock D, Anderson DD, Hillberry BM, Peacock M, Johnston CC. Impact of exercise on bone health and contraindication of oral contraceptive use in young women. Med Sci Sports Exerc. 2001;33(6):873–80.

    Article  CAS  PubMed  Google Scholar 

  64. Burr DB, Yoshikawa T, Teegarden D, Lyle R, McCabe G, McCabe LD, Weaver CM. Exercise and oral contraceptive use suppress the normal age-related increase in bone mass and strength of the femoral neck in women 18–31 years of age. Bone. 2000;27(6):855–63.

    Article  CAS  PubMed  Google Scholar 

  65. Hartard M, Bottermann P, Bartenstein P, Jeschke D, Schwaiger M. Effects on bone mineral density of low-dosed oral contraceptives compared to and combined with physical activity. Contraception. 1997;55(2):87–90.

    Article  CAS  PubMed  Google Scholar 

  66. Hartard M, Kleinmond C, Kirchbichler A, Jeschke D, Wiseman M, Weissenbacher ER, Felsenberg D, Erben RG. Age at first oral contraceptive use as a major determinant of vertebral bone mass in female endurance athletes. Bone. 2004;35(4):836–41.

    Article  CAS  PubMed  Google Scholar 

  67. Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 2001;98(4):576–82.

    CAS  PubMed  Google Scholar 

  68. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol. 2004;103(5 Pt 1):899–906.

    Article  CAS  PubMed  Google Scholar 

  69. Hartard M, Kleinmond C, Luppa P, Zelger O, Egger K, Wiseman M, Weissenbacher ER, Felsenberg D, Erben RG. Comparison of the skeletal effects of the progestogens desogestrel and levonorgestrel in oral contraceptive preparations in young women: controlled, open, partly randomized investigation over 13 cycles. Contraception. 2006;74(5):367–75.

    Article  CAS  PubMed  Google Scholar 

  70. Endrikat J, Mih E, Dusterberg B, Land K, Gerlinger C, Schmidt W, Felsenberg D. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception. 2004;69(3):179–87.

    Article  CAS  PubMed  Google Scholar 

  71. Gai L, Jia Y, Zhang M, Gai P, Wang S, Shi H, Yu X, Liu Y. Effect of two kinds of different combined oral contraceptives use on bone mineral density in adolescent women. Contraception. 2012;86(4):332–6.

    Article  CAS  PubMed  Google Scholar 

  72. Gargano V, Massaro M, Morra I, Formisano C, Carlo CD, Nappi C. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception. 2008;78(1):10–5.

    Article  CAS  PubMed  Google Scholar 

  73. Nappi C, Di Spiezio Sardo A, Greco E, Tommaselli GA, Giordano E, Guida M. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density. Obstet Gynecol. 2005;105(1):53–60.

    Article  CAS  PubMed  Google Scholar 

  74. Sordal T, Grob P, Verhoeven C. Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17beta-estradiol in comparison to levonorgestrel/ethinylestradiol. Acta Obstet Gynecol Scand. 2012;91(11):1279–85.

    Article  PubMed  Google Scholar 

  75. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25(5):693–721.

    Article  CAS  PubMed  Google Scholar 

  76. Leger J, Mercat I, Alberti C, Chevenne D, Armoogum P, Tichet J, Czernichow P. The relationship between the GH/IGF-I axis and serum markers of bone turnover metabolism in healthy children. Eur J Endocrinol. 2007;157(5):685–92.

    Article  CAS  PubMed  Google Scholar 

  77. Hansen M, Miller BF, Holm L, Doessing S, Petersen SG, Skovgaard D, Frystyk J, Flyvbjerg A, Koskinen S, Pingel J, Kjaer M, Langberg H. Effect of administration of oral contraceptives in vivo on collagen synthesis in tendon and muscle connective tissue in young women. J Appl Physiol (1985). 2009;106(4):1435–43.

    Article  CAS  Google Scholar 

  78. Gibbs JC, Williams NI, De Souza MJ. Prevalence of individual and combined components of the female athlete triad. Med Sci Sports Exerc. 2013;45(5):985–96.

    Article  PubMed  Google Scholar 

  79. Loucks AB, Verdun M, Heath EM. Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. J Appl Physiol (1985). 1998;84(1):37–46.

    CAS  Google Scholar 

  80. Nattiv A, Loucks AB, Manore MM, Sanborn CF, Sundgot-Borgen J, Warren MP. American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc. 2007;39(10):1867–82.

    Article  PubMed  Google Scholar 

  81. De Souza MJ, Nattiv A, Joy E, Misra M, Williams NI, Mallinson RJ, Gibbs JC, Olmsted M, Goolsby M, Matheson G. 2014 female athlete triad coalition consensus statement on treatment and return to play of the female athlete triad: 1st International Conference held in San Francisco, California, May 2012 and 2nd International Conference held in Indianapolis, Indiana, May 2013. Br J Sports Med. 2014;48(4):289.

    Article  PubMed  Google Scholar 

  82. De Souza MJ, Nattiv A, Joy E, Misra M, Williams NI, Mallinson RJ, Gibbs JC, Olmsted M, Goolsby M, Matheson G. 2014 female athlete triad coalition consensus statement on treatment and return to play of the female athlete triad: 1st International Conference held in San Francisco, CA, May 2012, and 2nd International Conference held in Indianapolis, IN, May 2013. Clin J Sport Med. 2014;24(2):96–119.

    PubMed  Google Scholar 

  83. Carlson JL, Curtis M, Halpern-Felsher B. Clinician practices for the management of amenorrhea in the adolescent and young adult athlete. J Adolesc Health. 2007;40(4):362–5.

    Article  PubMed  Google Scholar 

  84. Mallinson RJ, De Souza MJ. Current perspectives on the etiology and manifestation of the “silent” component of the female athlete triad. Int J Womens Health. 2014;6:451–67.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Kinesiology, Pennsylvania State University, 16802, University Park, PA, USA

    Heather C. M. Allaway MS

  2. Department of Kinesiology, Pennsylvania State University, 104 Noll Laboratory, 16802, University Park, PA, USA

    Rebecca J. Mallinson PhD & Mary Jane De Souza PhD

Authors
  1. Heather C. M. Allaway MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca J. Mallinson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary Jane De Souza PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary Jane De Souza PhD .

Editor information

Editors and Affiliations

  1. Department of Morphological Sciences, University of Cordoba Department of Morphological Sciences, Cordoba, Spain

    Diana Vaamonde

  2. Division of Medical Physiology, Stellenbosch University , Tygerberg, South Africa

    Stefan S du Plessis

  3. Cleveland Clinic Foundation, American Centre for Reproductive Medicin Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Ashok Agarwal

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Allaway, H., Mallinson, R., De Souza, M. (2016). Impact of Combined Oral Contraceptive Use on Exercise and Health in Female Athletes. In: Vaamonde, D., du Plessis, S., Agarwal, A. (eds) Exercise and Human Reproduction. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3402-7_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3402-7_17

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-3400-3

  • Online ISBN: 978-1-4939-3402-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation